Professor Jonathan Wadsley

All publications

Journal articles

• Danson S, Sirois F, Fradley K, Wadsley J, Ray J, Bishop R, Horsman J, Mann C, Chantry-Groves L, Young M & Bentall R (2023) Mental health burden for NHS healthcare staff during the COVID-19 pandemic: First results of a longitudinal survey. Heliyon, e13765-e13765.
• Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K , Anthoney A et al (2023) Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 trial.. Journal of Clinical Oncology, 41(4_suppl), 593-593.
• McNamara MG, Swain J, Craig Z, Sharma R, Faluyi OO, Wadsley J, Morgan C, Wall LR, Chau I, Reed N , Sarker D et al (2023) NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).. Journal of Clinical Oncology, 41(4_suppl), 646-646.
• Corrie PG & Wadsley J (2023) Safeguarding Clinical Research in the National Health Service. Clinical Oncology.
• Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe C, Sripadam R, Mukherjee S, Soonawalla Z, Wadsley J , Al-Mukhtar A et al (2022) Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. The Lancet Gastroenterology & Hepatology.
• Lorimer C, Cheng L, Chandler R, Garcez K, Gill V, Graham K, Grant W, Sardo Infirri S, Wadsley J, Wall L , Webber N et al (2022) Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer – Real-World Outcomes From UK Centres. Clinical Oncology.
• Wadsley J, Beasley M, Garcez K, Hoy S, Newbold K & Boelaert K (2022) Guidelines on the Use of Systemic Therapy in Patients with Advanced Thyroid Cancer. Clinical Oncology.
• Hillary SL, Chooi JE, Wadsley J, Newell-Price JD, Brown NJ & Balasubramanian SP (2022) Quality of life in post-surgical hypoparathyroidism (PoSH) in thyroid and parathyroid surgery. World Journal of Surgery, 46(12), 3025-3033.
• Craig Z, Swain J, Sharma R, Faluyi OO, Wadsley J, Morgan C, Wall LR, Chau I, Reed NS, Sarker D , Margetts J et al (2022) Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy.. Journal of Clinical Oncology, 40(28_suppl), 293-293.
• Lamarca A, Palmer D, Wasan HS, Ross P, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K , Anthoney A et al (2022) 54MO Quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial. Annals of Oncology, 33, S564-S565.
• Wadsley J, Armstrong N, Bassett-Smith V, Beasley M, Chandler R, Cluny L, Craig AJ, Farnell K, Garcez K, Garnham N , Graham K et al (2022) Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK. Clinical Oncology.
• Damm M, Efremov L, Jalal M, Nadeem N, Dober J, Michl P, Wohlgemuth W, Wadsley J, Hopper A, Krug S & Rosendahl J (2022) Body composition parameters as survival predictors in patients with pancreatic cancer – A retrospective multicenter analysis. Zeitschrift für Gastroenterologie, 60(08), e530-e530.
• Abani O, Abbas A, Abbas F, Abbas J, Abbas K, Abbas M, Abbasi S, Abbass H, Abbott A, Abbott A , Abdallah N et al (2022) Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. The Lancet, 400(10349), 359-368.
• Lee RW, Danson S, Elliot M, Park EI, Pinkney TD, Shaw CE, Vimalachandran D, Maughan T, Seymour M, Corrie P & Wadsley J (2022) Importance of clinical research for the UK's 10-year cancer plan. The Lancet Oncology. View this article in WRRO
• McNamara MG, Swain J, Craig Z, Sharma R, Faluyi OO, Wadsley J, Morgan C, Wall LR, Chau I, Reed N , Sarker D et al (2022) NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).. Journal of Clinical Oncology, 40(16_suppl), 4005-4005.
• Lamarca A, Palmer D, Wasan H, Ross P, Ting Ma Y, Arora A, Falk S, Gillmore R, Wadsley J, Patel K , Anthoney A et al (2022) P-88 Clinical role of tumour markers in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial. Annals of Oncology, 33, S280-S280.
• Ashley L, Kassim S, Kellar I, Kidd L, Mair F, Matthews M, Price M, Swinson D, Taylor J, Velikova G & Wadsley J (2022) Identifying ways to improve diabetes management during cancer treatments (INDICATE): protocol for a qualitative interview study with patients and clinicians. BMJ Open, 12(2).
• Teoh S, Sabbagh A, Wadsley J, Low L, Harrison C, O'Hare J, Goody R, Summers K, Wilson D, Walther J , Wilson F et al (2022) Hypofractionated radiotherapy to the pancreas: U.K. experience.. Journal of Clinical Oncology, 40(4_suppl), 525-525.
• Shotton K, Walsh H, Tahir F, Wadsley J, Lim CBB & Aziz S (2022) A rare case of NUT carcinoma arising in the thyroid. Diagnostic Histopathology.
• Saha A, Wadsley J, Sirohi B, Goody R, Ulahannan D, Wilson D, Collinson F & Anthony A (2021) 1476P Is it worth adding concurrent chemo-radiotherapy or radiotherapy on the top of neoadjuvant chemotherapy in the management of borderline resectable and locally advanced pancreatic adenocarcinoma? A systematic review. Annals of Oncology, 32, s1090.
• Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K , Anthoney A et al (2021) Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply. The Lancet Oncology, 22(7), e288-e289.
• Fong C, Patel B, Peckitt C, Bourmpaki E, von Loga K, Begum R, Davidson M, Anandappa G, Cafferkey C, Watkins DJ , Rao S et al (2021) Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.. Journal of Clinical Oncology, 39(15_suppl), 4015-4015.
• Vu QD, Fong C, von Loga K, Raza SEA, Nava Rodrigues D, Patel B, Peckitt C, Begum R, Athauda A, Starling N , Chau I et al (2021) Digital histological markers based on routine H&E slides to predict benefit from maintenance immunotherapy in esophagogastric adenocarcinoma.. Journal of Clinical Oncology, 39(15_suppl), e16074-e16074.
• Hall PS, Swinson D, Cairns DA, Waters JS, Petty R, Allmark C, Ruddock S, Falk S, Wadsley J, Roy R , Tillett T et al (2021) Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial.. JAMA Oncol.
• Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K , Anthoney A et al (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.. Lancet Oncol.
• Taprogge J, Wadsley J, Miles E & Flux GD (2021) Recommendations for multicentre clinical trials involving dosimetry for molecular radiotherapy. Clinical Oncology, 33(2), 131-136.
• Wadsley J & Flux G (2021) Molecular Radiotherapy Comes of Age. Clinical Oncology, 33(2), 65-67.
• Neoptolemos J, Palmer D, Gahneh P, Valle J, Cunningham D, Wadsley J, Meyer T, Anthoney A, Glimelius B, Falk S , Segersvard R et al (2020) ESPAC-4: A randomized controlled phase III trial of adjuvant gemcitabine (GEM) and capecitabine (CAP) versus gemcitabine in resected pancreatic ductal adenocarcinoma: five year follow up.. Pancreatology, 20, S17-S18.
• Corrie PG, Qian W, Basu B, Valle JW, Falk S, lwuji C, Wasan H, Palmer D, Scott-Brown M, Wadsley J , Arif S et al (2020) Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. British Journal of Cancer, 122(12), 1760-1768.
• Ghaneh P, Palmer DH, Cicconi S, Halloran C, Psarelli EE, Rawcliffe CL, Sripadam R, Mukherjee S, Wadsley J, Al-Mukhtar A , Jiao LR et al (2020) ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.. Journal of Clinical Oncology, 38(15_suppl), 4505-4505.
• Neoptolemos JP, Palmer DH, Ghaneh P, Valle JW, Cunningham D, Wadsley J, Meyer T, Anthoney A, Glimelius B, Falk S , Segersvard R et al (2020) ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.. Journal of Clinical Oncology, 38(15_suppl), 4516-4516.
• Arambewela MH, Wijesinghe AM, Randhawa K, Bull M, Wadsley J & Balasubramanian SP (2020) A pragmatic assessment of the British Thyroid Association “U classification” of thyroid nodules with a focus on their follow-up. Clinical Radiology, 75(6), 466-473.
• Craig Z, Swain J, Batman E, Wadsley J, Reed N, Faluyi O, Cave J, Sharma R, Chau I, Wall L , Lamarca A et al (2020) NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open, 10(2). View this article in WRRO
• Cunningham D, Fong CYK, Peckitt C, Anandappa G, Davidson M, Patel B, Turner A, Begum R, Cafferkey C, von Loga K , Rebelatto M et al (2020) Evaluating maintenance therapies in advanced oesophago-gastric adenocarcinoma (OGA): Interim analysis and biomarker results from the PLATFORM study.. Journal of Clinical Oncology, 38(4_suppl), 282-282.
• Reed N, Glen H, Gerrard G, Good J, Lei M, Lyon AR, Strachan M, Wadsley J & Newbold K (2020) Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer. Clinical Oncology, 32(5), e145-e153.
• Hanna CR, Lynskey DM, Wadsley J, Appleyard SE, Anwar S, Miles E, Gower J, Hall E, Coles CE & Hanna GG (2020) Radiotherapy Trial Set-up in the UK: Identifying Inefficiencies and Potential Solutions. Clinical Oncology, 32(4), 266-275.
• Chalmers AJ, Chan C, Sebag-Montefiore D, Sebag-Montefiore D, Evans M, Chalmers A, McKenna G, Miles E, Wadsley J, Williams K , Stephens R et al (2020) CTRad 10 Years On: From 10-point Plan to Top 10 Achievements. Clinical Oncology, 32(1), 9-12.
• Swinson DE, Hall P, Lord S, Marshall H, Ruddock S, Allmark C, Cairns D, Waters J, Wadsley J, Falk S , Roy R et al (2019) OPTIMIZING CHEMOTHERAPY FOR FRAIL AND/OR ELDERLY PATIENTS WITH ADVANCED GASTROESOPHAGEAL CANCER (AGOAC): THE GO2 PHASE III TRIAL. Journal of Geriatric Oncology, 10(6), S8-S8.
• Tay J, Marsh A, Wadsley J, Sabbagh A, Darby S & Crossley R (2019) Peri-operative FLOT versus ECX chemotherapy in operable lower oesophageal adenocarcinoma – a South Yorkshire experience. Clinical Oncology, 31, e8-e8.
• Jones RP, Psarelli E-E, Jackson R, Ghaneh P, Halloran CM, Palmer DH, Campbell F, Valle JW, Faluyi O, O’Reilly DA , Cunningham D et al (2019) Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 154(11), 1038-1038.
• Brown SR, Hall A, Buckley HL, Flanagan L, Gonzalez de Castro D, Farnell K, Moss L, Gregory R, Newbold K, Du Y , Flux G et al (2019) Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. BMC Cancer, 19(1). View this article in WRRO
• Jalal M, Campbell JA, Wadsley J & Hopper AD (2019) Can digital skeletal muscle index predict palliative chemotherapy uptake before patients undergo endoscopic pancreatic biopsy?. Pancreatology, 19, S106-S107.
• Jalal M, Campbell JA, Wadsley J & Hopper AD (2019) OWE-29 Can digital skeletal muscle index predict palliative chemotherapy uptake before patients undergo endoscopic pancreatic biopsy?. Pancreas.
• Hall PS, Swinson D, Waters JS, Wadsley J, Falk S, Roy R, Tillett T, Nicoll J, Cummings S, Grumett SA , Kamposioras K et al (2019) Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.. Journal of Clinical Oncology, 37(15_suppl), 4006-4006.
• Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K , Anthoney A et al (2019) ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.. Journal of Clinical Oncology, 37(15_suppl), 4003-4003.
• McNamara MG, Swain J, Craig Z, Wadsley J, Reed N, Faluyi OO, Lamarca A, Hubner R, Mansoor W, Sarker D , Howard HC et al (2019) NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).. Journal of Clinical Oncology, 37(15_suppl), TPS4158-TPS4158.
• Lee KA, Sharabiani MTA, Tumino D, Wadsley J, Gill V, Gerrard G, Sindhu R, Gaze MN, Moss L & Newbold K (2019) Differentiated Thyroid Cancer in Children: A UK Multicentre Review and Review of the Literature. Clinical Oncology, 31(6), 385-390.
• Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M , Wasan H et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. The Lancet Oncology, 20(5), 663-673.
• Tappenden P, Carroll C, Hamilton J, Kaltenthaler E, Wong R, Wadsley J, Moss L & Balasubramanian S (2019) Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Health Technology Assessment, 23(8), 1-144. View this article in WRRO
• Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran S-E, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J , Ducreux M et al (2019) Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 20(3), 420-435.
• Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C & Hackshaw A (2019) Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. The Lancet Diabetes and Endocrinology, 7(1), 44-51. View this article in WRRO
• Goh V, Smye SW, Allen L, Ashcroft J, Cooper M, Gilbert FJ, Goh V, Graham R, Keevil S, Matthews J , Mould A et al (2019) The National Institute for Health Research: making an impact in imaging research. Clinical Radiology, 74(3), 242-246.
• Smyth EC, Cafferkey C, Loehr A, Waddell T, Begum R, Peckitt C, Harding TC, Nguyen M, Okines AF, Raponi M , Rao S et al (2018) Genomic loss of heterozygosity and survival in the REAL3 trial. Oncotarget, 9(94), 36654-36665. View this article in WRRO
• Petty RD, Dahle-Smith A, Stevenson DAJ, Osborne A, Massie D, Clark C, Murray GI, Dutton SJ, Roberts C, Chong IY , Mansoor W et al (2017) Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. Journal of Clinical Oncology, 35(20), 2279-2287.
• Wadsley J, Gregory R, Flux G, Newbold K, Du Y, Moss L, Hall A, Flanagan L & Brown SR (2017) SELIMETRY- a multicentre I-131 dosimetry trial: a clinical perspective. The British Journal of Radiology, 90(1073). View this article in WRRO
• Newbold KL, Flux G & Wadsley J (2017) Radioiodine for High Risk and Radioiodine Refractory Thyroid Cancer: Current Concepts in Management. Clinical Oncology, 29(5), 307-309.
• Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J , Darby S et al (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. The Lancet, 389(10073), 1011-1024. View this article in WRRO
• Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW , Propper D et al (2017) Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. The Lancet Oncology.
• Himsworth JM, Wadsley J, Brown C, Hallam A & Singleton M (2017) Day-case Treatment with Radioactive I-131 for Thyroid Cancer. Clinical Oncology.
• Akram R, Wiltshire JJ, Wadsley J & Balasubramanian SP (2016) Adult Thyroglossal Duct Carcinoma of Thyroid Epithelial Origin: A Retrospective Observational Study. Indian Journal of Otolaryngology and Head and Neck Surgery, 1-6. View this article in WRRO
• Sahasrabudhe R, Stultz J, Williamson J, Lott P, Estrada A, Bohorquez M, Palles C, Polanco-Echeverry G, Jaeger E, Martin L , Echeverry MM et al (2016) The HABP2 G534E Variant Is an Unlikely Cause of Familial Nonmedullary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism, 101(3), 1098-1103.
• Danson SJ, Rowland C, Rowe R, Ellis S, Crabtree C, Horsman JM, Wadsley J, Hatton MQ, Woll PJ & Eiser C (2016) The relationship between smoking and quality of life in advanced lung cancer patients: a prospective longitudinal study. Supportive Care in Cancer, 24(4), 1507-1516. View this article in WRRO
• Rowland C, Danson SJ, Rowe R, Merrick H, Woll PJ, Hatton MQ, Wadsley J, Ellis S, Crabtree C, Horsman JM & Eiser C (2016) Quality of life, support and smoking in advanced lung cancer patients: a qualitative study. BMJ Supportive & Palliative Care, 6(1), 35-42.
• Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T , Cunningham D et al (2014) Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. The Lancet Oncology, 15(8), 829-840.
• Edafe O, Wadsley J, Harrison BJ & Balasubramanian SP (2014) Treatment related morbidity in differentiated thyroid cancer–a survey of clinicians. Thyroid Research, 7(1), 3-3. View this article in WRRO
• Annels NE, Shaw VE, Gabitass RF, Billingham L, Corrie P, Eatock M, Valle J, Smith D, Wadsley J, Cunningham D , Pandha H et al (2014) The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunology, Immunotherapy, 63(2), 175-183.
• Balasubramanian SP, Brignall J, Lin HY, Stephenson TJ, Wadsley J, Harrison BJ, Craig WL, Smart L & Krukowski Z (2014) Sentinel node biopsy in papillary thyroid cancer—what is the potential?. Langenbeck's Archives of Surgery, 399(2), 245-251.
• Ford HER, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW , Swinson D et al (2014) Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. The Lancet Oncology, 15(1), 78-86.
• Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, Lowe C, Seligmann JF, Wadsley J, Maisey N , Chau I et al (2013) Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial. The Lancet Oncology, 14(8), 749-759.
• Middleton GW, Valle JW, Wadsley J, Propper D, Coxon FY, Ross PJ, Madhusudan S, Roques T, Cunningham D, Corrie P , Greenhalf W et al (2013) A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.. Journal of Clinical Oncology, 31(15_suppl), LBA4004-LBA4004.
• Cook N, Marshall A, Blazeby JM, Bridgewater JA, Wadsley J, Coxon FY, Mansoor W, Madhusudan S, Falk S, Middleton GW , Swinson D et al (2013) Cougar-02: A randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma.. Journal of Clinical Oncology, 31(15_suppl), 4023-4023.
• Waddell T, Chau I, Cunningham D, Gonzalez D, Frances A, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J , Ferry D et al (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. LANCET ONCOLOGY, 14(6), 481-489.
• Middleton G, Brown S, Lowe C, Maughan T, Gwyther S, Oliver A, Richman S, Blake D, Napp V, Marshall H , Wadsley J et al (2013) A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). European Journal of Cancer, 49(16), 3507-3516.
• Okines AFC, Gonzalez de Castro D, Cunningham D, Chau I, Saffery C, Barbachano Y, Waddell TS, Puckey L, Hulkki Wilson S, Eltahir Z , Band M et al (2013) Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. European Journal of Cancer.
• Agbamu DA, Day N, Walsh CJ, Hendrickse CW, Langman G, Pallan A, Lowe A, Ostrowski J, Steward M, Callaway M , Falk S et al (2012) Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: The pilot phase of a randomised controlled trial. The Lancet Oncology, 13(11), 1152-1160.
• Murray LJ, Din OS, Kumar VS, Dixon LM & Wadsley JC (2012) Palliative radiotherapy in patients with esophageal carcinoma: A retrospective review. Practical Radiation Oncology, 2(4), 257-264.
• Waddell TS, Chau I, Barbachano Y, Gonzalez de Castro D, Wotherspoon A, Saffery C, Middleton GW, Wadsley J, Ferry DR, Mansoor W , Crosby TDL et al (2012) A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).. Journal of Clinical Oncology, 30(15_suppl), LBA4000-LBA4000.
• Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R , Smellie J et al (2012) Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.. N Engl J Med, 366(18), 1674-1685.
• Jones AM, Howarth KM, Martin L, Gorman M, Mihai R, Moss L, Auton A, Lemon C, Mehanna H, Mohan H , Clarke SEM et al (2012) Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24.. J Med Genet, 49(3), 158-163. View this article in WRRO
• Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, Tenesa A, Spain S, Broderick P, Ooi L-Y , Domingo E et al (2012) Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nature Genetics.
• Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, Tenesa A, Spain S, Broderick P, Ooi LY , Domingo E et al (2012) Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nature Genetics, 44(7), 770-776.
• Roth LM, Talerman A, Wadsley J & Karseladze AI (2010) Risk factors in thyroid-type carcinoma arising in ovarian struma: a report of 15 cases with comparison to ordinary struma ovarii. HISTOPATHOLOGY, 57(1), 148-152.
• Zekri JM, Manifold IH & Wadsley JC (2006) Metastatic Struma Ovarii: Late Presentation, Unusual Features and Multiple Radioactive Iodine Treatments. Clinical Oncology, 18(10), 768-772.
• Wadsley JC & Bentzen SM (2004) Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer. International Journal of Radiation Oncology Biology Physics, 60(5), 1405-1409.
• Wadsley JC, Patel M, Tomlins CDC & Gildersleve JQ (2003) Iridium-192 implantation for T1 and T2a carcinoma of the tongue and floor of mouth: Retrospective study of the results of treatment at the Royal Berkshire Hospital. British Journal of Radiology, 76(906), 414-417.
• Wadsley J, Balasubramanian S, Madani G, Munday J, Roques T, Rowe C, Touska P & Boelaert K () Consensus statement on the management of incidentally discovered FDG avid thyroid nodules in patients being investigated for other cancers. Clinical Endocrinology.
• Wadsley J () Redifferentiation therapy for iodine refractory differentiated thyroid cancers- current status. Thyroid.
• Karunanayaka M, Wadsley J & Munir A () Parathyroid related peptide (PTHrP) secreting pancreatic neuroendocrine tumour (PNET): a case of PTHrP, hypercalcaemia and osteoarthrosis (OA) controlled by somatostatin analogue therapy (SSA). Endocrine Abstracts.
• Wadsley J () Novel target therapies for advanced thyroid cancers. Endocrine Abstracts.
• Elamin A, Hussein Z & Wadsley J () A rare Presentation of Carcinoid Crisis Following Radioactive Iodine Treatment for Thyroid Cancer in a Patient with Metastatic Midgut Neuroendocrine Tumour. Endocrine Abstracts.
• Bridgewater J, Fletcher P, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M , Wasan H et al () Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. Journal of Clinical Oncology.
• Jalal M, Campbell JA, Wadsley J & Hopper AD () Computed Tomographic Sarcopenia in Pancreatic Cancer: Further Utilization to Plan Patient Management. Journal of Gastrointestinal Cancer.
• Walshaw EG, Smith M, Kim D, Wadsley J, Kanatas A & Rogers SN () Systematic review of health-related quality of life following thyroid cancer. Tumori Journal, 030089162110250-030089162110250.
• Smyth EC, Vlachogiannis G, Hedayat S, Harbery A, Hulkki-Wilson S, Salati M, Kouvelakis K, Fernandez-Mateos J, Cresswell GD, Fontana E , Seidlitz T et al () EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. Gut.
• Moss L, Cox C, Wadsley J, Newbold K, Strachan MWJ, Druce M, Tolley N, Graham K, Jefferies S, Fresco L , Sivabalasingham S et al () Medullary Thyroid Cancer Patient’s Assessment of Quality of Life Tools: Results from the QaLM Study. European Thyroid Journal, 1-7.
• O'Connor D, Brown M, Bowdery R, Eatock M, Hulme C, Maraveyas A, Robinson R, Turkington RC, Vince R, Wadsley J & Prue G () PancREatic Cancer and Individualised Supervised Exercise (PRECISE): a feasibility trial protocol for patients with resectable pancreatic ductal adenocarcinoma. AMRC Open Research, 2, 22-22.
• O'Connor D, Brown M, Bowdery R, Eatock M, Hulme C, Maraveyas A, Robinson R, Turkington RC, Vince R, Wadsley J & Prue G () PancREatic Cancer and Individualised Supervised Exercise (PRECISE): a feasibility trial protocol for patients with resectable pancreatic ductal adenocarcinoma. AMRC Open Research, 2, 22-22.
• Gregory RA, Murray I, Gear J, Leek F, Chittenden S, Fenwick A, Wevrett J, Scuffham J, Tipping J, Murby B , Jeans S et al () Standardised quantitative radioiodine SPECT/CT Imaging for multicentre dosimetry trials in molecular radiotherapy. Physics in Medicine & Biology, 64(24), 245013-245013.
• Maynard A, Hill S, Hallam A, Sabbagh A, Brown C, Munir A, Newell-Price J & Wadsley J () Sheffield experience of administering Lutathera as a day case treatment. Endocrine Abstracts.
• Uchambally M, Munir A, Wadsley J & Lorenz E () Efficacy of somatostatin analogues in managing hypercalcaemia due to PTHrP in a well differentiated metastatic pancreatic neuroendocrine tumour and discussion of modern treatment options: A clinical case. Endocrine Abstracts.
• Pillai S, Munir A, Lorenz E & Wadsley J () Chronic diarrhoea - a rare endocrine cause. Endocrine Abstracts.

Conference proceedings papers

• Hillary S, Glenister E, Chooi JE, Farnell K, Grey J, Wadsley J, Newell-Price J, Brown N & Balasubramanian S (2022) Quality of life in post-surgical hypoparathyroidism (PoSH). BRITISH JOURNAL OF SURGERY, Vol. 109
• McNamara MG, Swain J, Craig Z, Sharma R, Faluyi OO, Wadsley J, Morgan C, Wall LR, Chau I, Reed N , Sarker D et al (2022) NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC).. JOURNAL OF CLINICAL ONCOLOGY, Vol. 40(16)
• Craig Z, Swain J, Sharma R, Faluyi OO, Wadsley J, Morgan C, Wall LR, Chau I, Reed NS, Sarker D , Margetts J et al (2022) Health-related quality of life (HRQoL) in patients (pts) with progressive, poorly differentiated, extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) enrolled in NET-02: A phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy. JOURNAL OF CLINICAL ONCOLOGY, Vol. 40(28) (pp 293-293)
• Walsh H, Shotton K, Tahir F, Wadsley J, Lim CBB & Aziz S (2021) A Rare Case of Thyroid NUT Carcinoma. JOURNAL OF PATHOLOGY, Vol. 255 (pp S27-S27)
• Vavrova L, Gear J, Taprogge J, Murray I, Brown S, Swain J, Wadsley J & Flux G (2021) Pre-therapy I-123-NaI dosimetry for predicting salivary gland absorbed doses from I-131-NaI therapy. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol. 48(SUPPL 1) (pp S135-S136)
• Ghaneh P, Palmer D, Cicconi S, Halloran C, Psarelli E, Rawcliffe C, Sripadam R, Mukherjee S, Wadsley J, Al-Mukhtar A , Jiao L et al (2020) ESPAC-5F: Four arm, international randomised phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. Pancreatology, Vol. 20 (pp S4-S5)
• Neoptolemos JP, Palmer DH, Ghaneh P, Valle JW, Cunningham D, Wadsley J, Meyer T, Anthoney A, Glimelius B, Falk S , Segersvard R et al (2020) ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(15)
• Cunningham D, Fong CYK, Peckitt C, Anandappa G, Davidson M, Patel B, Turner A, Begum R, Cafferkey C, von Loga K , Rebelatto M et al (2020) Evaluating maintenance therapies in advanced oesophago-gastric adenocarcinoma (OGA): Interim analysis and biomarker results from the PLATFORM study. JOURNAL OF CLINICAL ONCOLOGY, Vol. 38(4)
• Taprogge J, Yusuf S, Gear J, Murray I, Leek F, Gregory RA, Wevrett J, Scuffham J, Tipping J, Murby B , Jeans S et al (2020) Predictive accuracy of pre-therapy I-123-NaI dosimetry for patients treated with I-131-NaI as part of the UK multi-centre SELIMETRY trial. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol. 47(SUPPL 1) (pp S317-S317)
• Ghaneh P, Palmer D, Cicconi S, Halloran CM, Jackson R, Rawcliffe C, Sripadam R, Mukherjee S, Wadsley J, Al-Muktar A , Jiao L et al (2020) ESPAC-5F: Four Arm, Prospective, Multicenter, International Randomized Phase II Trial of Immediate Surgery Compared With Neoadjuvant Gemcitabine Plus Capecitabine (GEMCAP) or FOLFIRINOX or Chemoradiotherapy (CRT) in Patients With Borderline Resectable Pancreatic Cancer. PANCREAS, Vol. 49(10) (pp 1410-1410)
• Ali A, Hodgkinson W, Wadsley J & Balasubramanian S (2019) Role of Thyroglobulin in Routine Monitoring of Differentiated Thyroid Carcinoma. BRITISH JOURNAL OF SURGERY, Vol. 106 (pp 17-17)
• Hall P, Swinson D, Lord S, Marshall H, Cairns D, Ruddock S, Batman E, Velikova G, Petty R, Waters J , Wadsley J et al (2019) Optimizing Chemotherapy for Frail and Elderly Patients with Advanced Gastroesophageal Cancer (aGOAC): the GO2 Phase III Trial. BRITISH JOURNAL OF CANCER, Vol. 121 (pp 22-23)
• Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K , Anthoney A et al (2019) ABC-06 vertical bar A randomised phase III study of Active Symptom Control (ASC) with/without mFOLFOX after progression to Cisplatin-Gemcitabine chemotherapy for patients with advanced biliary tract cancers. BRITISH JOURNAL OF CANCER, Vol. 121 (pp 19-19)
• Smyth E, Kouvelakis K, Cunningham D, Hahne JC, Peckitt C, Vlachogiannis G, Watkins D, Rao S, Starling N, Wilson SH , Waddell TS et al (2018) EGFR amplification (amp) and survival in the REAL-3 trial. ANNALS OF ONCOLOGY, Vol. 29
• Palmer DH, Ross PJ, Silcocks P, Greenhalf W, Faluyi O, Ma YT, Wadsley J, Rawcliffe C, Neoptolemos J, Valle JW , Wasan H et al (2018) ACELARATE: A randomised phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinoma. ANNALS OF ONCOLOGY, Vol. 29
• Smyth E, Kouvelakis K, Cunningham D, Hahne JC, Peckitt C, Vlachogiannis G, Watkins D, Rao S, Starling N, Wilson SH , Waddell TS et al (2018) EGFR amplification (amp) and survival in the REAL-3 trial. Annals of Oncology, Vol. 29 (pp viii217-viii217)
• Harrison Palmer D, Ross PJ, Silcocks P, Greenhalf W, Faluyi O, Ma YT, Wadsley J, Rawcliffe C, Neoptolemos J, Valle JW , Wasan H et al (2018) ACELARATE: A randomised phase III, open label, clinical study comparing NUC-1031 with gemcitabine in patients with metastatic pancreatic carcinoma. Annals of Oncology, Vol. 29 (pp viii269-viii270)
• Gregory R, Gear J, Leek F, Anderson C, Hall D, Polydor H, Beasley M, Oyen W, Du Y, Newbold K , Brown S et al (2018) SPECT/CT-based Dosimetry for a Multicentre Trial of Selumetinib Enhanced Radioiodine Treatment of Differentiated Thyroid Cancer: Preliminary Results. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol. 45 (pp S284-S285)
• Evans A, Jackson R, Shaw VE, Ghaneh P, Wadsley J, Valle JW, Wasan H, Falk S, Cunningham D, Coxon FY , Ross PJ et al (2018) Biomarker predication of efficacy to gemcitabine plus vandetanib in phase II, double blind multicentre randomised controlled trial of gemcitabine placebo in locally advanced or metastatic pancreatic carcinoma. Pancreatology, Vol. 18(4) (pp S127-S128)
• Jalal M, Wadsley J & Hopper A (2018) PTU-023 Endoscopic ultrasound biopsy prior to palliative treatment for pancreatic cancer: can we prevent unnecessary procedures?. Pancreas
• Garikipati S & Wadsley J (2018) Audit of outcomes from Chemoradiotherapy for locally advanced pancreatic cancer at Weston Park Hospital and comparison with SCALOP trial. European Journal of Surgical Oncology, Vol. 44 (pp S9-S9)
• Palmer DH, Ross PJ, Silcocks P, Greenhalf W, Faluyi OO, Ma YT, Wadsley J, Rawcliffe CL, Valle JW & Neoptolemos JP (2018) ACELARATE: A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with gemcitabine in patients with metastatic pancreatic carcinoma.. Journal of Clinical Oncology, Vol. 36(4_suppl) (pp TPS537-TPS537)
• Corrie P, Qian W, Gopinathan A, Williams M, Brais R, Valle JW, Basu B, Falk S, Iwuji C, Wasan H , Palmer D et al (2017) Strong tumour cytidine deaminase (CDA) staining predicts for improved survival associated with sequential nab-Paclitaxel (nabP) and gemcitabine (GEM) chemotherapy as first line treatment of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC). Annals of Oncology, Vol. 28 (pp v251-v252)
• Neoptolemos JP, Palmer D, Greenhalf W, Ghaneh P, Jackson R, Evans A, Shaw V, Wadsley J, Valle JW, Wasan H , Falk S et al (2017) Biomarker prediction of efficacy to vandetanib plus gemcitabine in a phase II double blind multicenter randomized placebo-controlled trial in locally advanced or metastatic pancreatic carcinoma.. Journal of Clinical Oncology, Vol. 35(15_suppl) (pp 4104-4104)
• Corrie P, Qian W, Basu B, Valle JW, Falk S, Iwuji C, Wasan HS, Palmer DH, Scott-Brown M, Wadsley J , Arif SS et al (2017) A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (mPDAC).. Journal of Clinical Oncology, Vol. 35(15_suppl) (pp 4100-4100)
• Primrose JN, Fox R, Palmer DH, Prasad R, Mirza D, Anthoney DA, Corrie P, Falk S, Wasan HS, Ross PJ , Wall LR et al (2017) Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.. Journal of Clinical Oncology, Vol. 35(15_suppl) (pp 4006-4006)
• Neoptolemos JP, Palmer D, Ghaneh P, Valle J, Cunningham D, Wadsley J, Meyer T, Anthoney A, Glimelius B, Falk S , Lind P et al (2016) ESPAC-4: A Multicenter, International, Randomized Controlled Phase III Trial of Adjuvant Combination Chemotherapy of Gemcitabine (GEM) and Capecitabine (CAP), Versus Monotherapy Gemcitabine in Patients With Resected Pancreatic Ductal Adenocarcinoma. PANCREAS, Vol. 45(10) (pp 1529-1529)
• Ramage J, Punia P, Faluyi O, Frilling A, Meyer T, Kapur G, Cave J, Wadsley J, Cummins S, Farrugia D , Starling N et al (2016) UK phase IV, observational study to assess quality of life in patients (pts) with pancreatic neuroendocrine tumours (pNETS) receiving treatment with everolimus: The “real-world” OBLIQUE study. Annals of Oncology, Vol. 27 (pp vi143-vi143)
• Neoptolemos JP, Palmer D, Ghaneh P, Valle JW, Cunningham D, Wadsley J, Meyer T, Anthoney A, Glimelius B, Falk S , Segersvard R et al (2016) ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, Vol. 34(18_suppl) (pp LBA4006-LBA4006)
• Neoptolemos J, Palmer D, Ghaneh P, Valle JW, Cunningham D, Wadsley J, Meyer T, Anthoney A, Glimelius B, Falk S , Segersvärd R et al (2016) ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. Pancreatology, Vol. 16(3) (pp S63-S63)
• Wiltshire JJ, Harrison BJ, Wadsley J & Balasubramanian SP (2015) 18. Thyroid cancer – Incidence trends and distribution patterns in South Yorkshire, United Kingdom. European Journal of Surgical Oncology (EJSO), Vol. 41(10) (pp S84-S85)
• Waddell TS, Chau I, Peckitt C, Gonzalez D, Wotherspoon A, Patel B, Middleton GW, Wadsley J, Ferry D, Mansoor W , Crosby TDL et al (2014) Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.. Journal of Clinical Oncology, Vol. 32(15_suppl) (pp 4067-4067)
• Neoptolemos JP, Greenhalf W, Cox TF, Costello E, Shaw V, Valle JW, Coxon FY, Wadsley J, Propper D, Ross PJ , Madhusudan S et al (2014) Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial.. Journal of Clinical Oncology, Vol. 32(15_suppl) (pp 4121-4121)
• Waddell TS, Chau I, Peckitt C, Patel B, Gonzalez de Castro D, Wotherspoon A, Middleton GW, Wadsley J, Ferry D, Mansoor W , Crosby TDL et al (2014) Prognostication in esophagogastric adenocarcinoma (OGA): Factors influencing overall survival (OS) in REAL3.. Journal of Clinical Oncology, Vol. 32(3_suppl) (pp 91-91)
• Middleton GW, Valle JW, Wadsley J, Propper D, Coxon FY, Ross PJ, Madhusudan S, Roques T, Cunningham D, Corrie P , Greenhalf W et al (2013) A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.. Journal of Clinical Oncology, Vol. 31(18_suppl) (pp LBA4004-LBA4004)
• Cook N, Marshall A, Blazeby JM, Bridgewater JA, Wadsley J, Coxon FY, Mansoor W, Madhusudan S, Falk S, Middleton GW , Swinson D et al (2013) Cougar-02: A randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma. JOURNAL OF CLINICAL ONCOLOGY, Vol. 31(15)
• Ford H, Marshall A, Wadsley J, Coxon FY, Mansoor W, Bridgewater JA, Madhusudan S, Falk S, Middleton GW, Swinson D , Chau I et al (2013) COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.. Journal of Clinical Oncology, Vol. 31(4_suppl) (pp LBA4-LBA4)
• Waddell TS, Reis-Filho J, Gonzalez-De-Castro D, Chau I, Wotherspoon A, Gupta S, Saffery C, Middleton G, Wadsley J & Cunningham D (2012) A RANDOMISED MULTICENTRE TRIAL OF EPIRUBICIN, OXALIPLATIN AND CAPECITABINE (EOC) plus PANITUMUMAB IN ADVANCED OESOPHAGO-GASTRIC CANCER (REAL3): UPDATED RESULTS. ANNALS OF ONCOLOGY, Vol. 23 (pp 224-224)
• Borad M, Reddy S, Bahary N, Uronis H, Sigal DS, Cohn AL, Schelman W, Stephenson J, Eng C & Ryan DP (2012) TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC). Annals of Oncology, Vol. 23 (pp ix224-ix224)
• Waddell TS, Chau I, Barbachano Y, Gonzalez de Castro D, Wotherspoon A, Saffery C, Middleton GW, Wadsley J, Ferry DR, Mansoor W , Crosby TDL et al (2012) A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).. Journal of Clinical Oncology, Vol. 30(18_suppl) (pp LBA4000-LBA4000)
• Danson S, Rowland C, Eiser C, Rowe R, Ellis S, Crabtree C, Horsman JM, Wadsley J, Hatton M & Woll P (2012) Implications of smoking for quality of life and illness perceptions of lung cancer patients. JOURNAL OF CLINICAL ONCOLOGY, Vol. 30(15)
• Middleton GW, Brown SR, Gwyther SJ, Maughan TS, Wadsley J, Chau I, Richman S, Olivier C, Marshall H & Seymour MT (2011) Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer - Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification. EUROPEAN JOURNAL OF CANCER, Vol. 47 (pp S420-S421)
• Seymour MT, Brown SR, Richman S, Middleton GW, Maughan T, Olivier C, Gwyther SJ, Wadsley J, Chau I, Hickish T , Dawson LK et al (2011) Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).. J Clin Oncol, Vol. 29(15_suppl) (pp 3523). United States
• Seymour MT, Brown SR, Richman S, Middleton GW, Maughan T, Olivier C, Gwyther SJ, Wadsley J, Chau I, Hickish T , Dawson LK et al (2011) Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).. Journal of Clinical Oncology, Vol. 29(15_suppl) (pp 3523-3523)
• Chau I, Okines AFC, Gonzalez de Castro D, Saffery C, Barbachano Y, Wotherspoon A, Puckey L, Hulkki Wilson S, Coxon FY, Middleton GW , Ferry DR et al (2011) REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, and molecular analysis from phase II.. Journal of Clinical Oncology, Vol. 29(15_suppl) (pp 4131-4131)
• Danson S, Shaw K, Bruce L, Wadsley J, Fisher P, Foran B, Mohanamurali J, Trigg M, Joyce P, Woll PJ & Hatton MQ (2007) Outreach chemotherapy: convenience versus quality?. LUNG CANCER, Vol. 57 (pp S5-S5)
• Arshad MF, Iqbal A, Bury J, Wadsley J & Munir A () Functional or non-function pancreatic NET; Novel use of a flash glucose monitoring system. Endocrine Abstracts

Preprints

• Wadsley J, Ainsworth G, Coulson AB, Garcez K, Moss L, Newbold K, Farnell K, Swain J, Howard H, Beasly M , Weaver A et al () Investigating the Clinical Benefit of Selumetinib in Resensitising Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy: Results of the SEL-I-METRY Phase II Trial.
• Jalal M, Campbell JA, Wadsley J & Hopper AD () Digital Detection of Sarcopenia in Pancreatic Cancer: Additional Utilization to Plan Patient Management, Research Square Platform LLC.
• Bridgewater J, Fletcher P, Palmer D, Malik H, Prasad R, Mirza D, Anthoney A, Corrie P, Falk S, Finch-Jones M , Wasan H et al () Long Term Outcomes and Exploratory Analyses of the Randomised Phase 3 BILCAP Study.
• Hall P, Swinson D, Cairns DA, Waters J, Petty R, Allmark C, Ruddock S, Falk S, Wadsley J, Roy R , Tillett T et al () Optimising Chemotherapy for Frail and Older Patients With Advanced Gastroesophageal Cancer: The GO2 Phase III Trial.
• Lamarca A, Palmer D, Wasan H, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K , Anthoney A et al () FOLFOX as Second-Line Chemotherapy for Advanced Biliary Tract Cancer.